Taken together, these studies highlight the critical role of Pak1 in regulating glucose metabolism, insulin sensitivity, and β‐cell survival, positioning Pak1 as a promising therapeutic target for T2D in addition to its promise as a target for obesity and cardiac dysfunction. This evidence concerns the gene PAK1 and obesity due to melanocortin 4 receptor deficiency.